Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04202601
What this trial is testing

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Peking University 80
Testing effectiveness (Phase 2)WithdrawnNCT03704077
What this trial is testing

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerCancer of the StomachStomach Cancer+1 more
Bristol-Myers Squibb
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Study completedNCT00253370
What this trial is testing

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Ended earlyNCT00848783
What this trial is testing

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Who this might be right for
Gastric CancerGastric AdenocarcinomaEsophageal Cancer
NYU Langone Health 8
Testing effectiveness (Phase 2)Looking for participantsNCT07026149
What this trial is testing

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Who this might be right for
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital 30
Not applicableActive Not RecruitingNCT06504615
What this trial is testing

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Who this might be right for
Gastric AdenocarcinomaGastro-esophageal Junction AdenocarcinomaEsophageal Adenocarcinoma (EAC)+1 more
Bristol-Myers Squibb 208
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07507916
What this trial is testing

Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
ctDNAGastric CancerGastroesophageal Junction (GEJ) Adenocarcinoma+1 more
Fudan University 32
Large-scale testing (Phase 3)Study completedNCT02494583
What this trial is testing

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Who this might be right for
Gastric Adenocarcinoma
Merck Sharp & Dohme LLC 763
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Testing effectiveness (Phase 2)Study completedNCT03662659
What this trial is testing

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Who this might be right for
Gastric CancerCancer of the StomachEsophagogastric Junction
Bristol-Myers Squibb 274
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07727993
What this trial is testing

Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction AdenocarcinomaPropranololSOX Chemotherapy+1 more
Ting Liu 49
Not applicableStudy completedNCT03528629
What this trial is testing

IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric CancerGastro-esophageal Junction (GEJ) Cancer
Astellas Pharma Inc 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT07143604
What this trial is testing

Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
AstraZeneca 33
Early research (Phase 1)Ended earlyNCT04594811
What this trial is testing

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
NeoImmuneTech 10
Testing effectiveness (Phase 2)UnknownNCT05218148
What this trial is testing

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Who this might be right for
HER2-positiveLocally Advanced Solid TumorImmunotherapy+4 more
Aiping Zhou 44
Large-scale testing (Phase 3)Active Not RecruitingNCT04208347
What this trial is testing

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Who this might be right for
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital 580
Testing effectiveness (Phase 2)Active Not RecruitingNCT03505320
What this trial is testing

Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Who this might be right for
Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more
Astellas Pharma Global Development, Inc. 143
Large-scale testing (Phase 3)WithdrawnNCT04859582
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC
Next Page